E Troncy1, M Francoeur, G Blaise. 1. Department of Anaesthesia, Centre Hospitalier de l'Université de Montréal-Pavillon Notre-Dame, Québec, Canada.
Abstract
PURPOSE: Although the analogy of nitric oxide (NO) to Endothelium-derived Relaxing Factor remains controversial, medical use of exogenous NO gas by inhalation has grown exponentially. This review presents the mechanisms of action of inhaled NO in pulmonary hypertension, hypoxaemia, inflammation and oedema, as well as its therapeutic and diagnostic indications with emphasis on acute respiratory distress syndrome (ARDS) and toxicology. SOURCE: Two medical databases (Current Contents, Medline) were searched for citations containing the above-mentioned key words to December 1996. Moreover, many presentations in congresses such as 4th International Meeting of Biology of Nitric Oxide, 52nd and 53rd Annual Meeting of Canadian Anaesthetists' Society or 10th Annual Meeting of European Association of Cardiothoracic Anaesthesiologists were used. PRINCIPAL FINDINGS: Inhaled NO is now recognized as an invaluable tool in neonatal and paediatric critical care, and for heart/lung surgery. Other clinical applications in adults, such as chronic obstructive pulmonary disease and ARDS, require a cautious approach. The inhaled NO therapy is fairly inexpensive, but it would seem that it is not indicated for everybody with regards to the paradigm of its efficiency and potential toxicity. The recent discovery of its anti-inflammatory and extrapulmonary effects open new horizons for future applications. CONCLUSION: Clinical use of inhaled NO was mostly reported in case series, properly designed clinical trials must now be performed to establish its real therapeutic role. These trials would permit adequate selection of the cardiopulmonary disorders, and subsequently the patients that would maximally benefit from inhaled NO therapy.
PURPOSE: Although the analogy of nitric oxide (NO) to Endothelium-derived Relaxing Factor remains controversial, medical use of exogenous NO gas by inhalation has grown exponentially. This review presents the mechanisms of action of inhaled NO in pulmonary hypertension, hypoxaemia, inflammation and oedema, as well as its therapeutic and diagnostic indications with emphasis on acute respiratory distress syndrome (ARDS) and toxicology. SOURCE: Two medical databases (Current Contents, Medline) were searched for citations containing the above-mentioned key words to December 1996. Moreover, many presentations in congresses such as 4th International Meeting of Biology of Nitric Oxide, 52nd and 53rd Annual Meeting of Canadian Anaesthetists' Society or 10th Annual Meeting of European Association of Cardiothoracic Anaesthesiologists were used. PRINCIPAL FINDINGS: Inhaled NO is now recognized as an invaluable tool in neonatal and paediatric critical care, and for heart/lung surgery. Other clinical applications in adults, such as chronic obstructive pulmonary disease and ARDS, require a cautious approach. The inhaled NO therapy is fairly inexpensive, but it would seem that it is not indicated for everybody with regards to the paradigm of its efficiency and potential toxicity. The recent discovery of its anti-inflammatory and extrapulmonary effects open new horizons for future applications. CONCLUSION: Clinical use of inhaled NO was mostly reported in case series, properly designed clinical trials must now be performed to establish its real therapeutic role. These trials would permit adequate selection of the cardiopulmonary disorders, and subsequently the patients that would maximally benefit from inhaled NO therapy.
Authors: Jean-Bernard Ruidavets; Sylvie Cassadou; Maxime Cournot; Vincent Bataille; Mariam Meybeck; Jean Ferrières Journal: J Epidemiol Community Health Date: 2005-08 Impact factor: 3.710
Authors: Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter Journal: Curr Med Chem Date: 2008 Impact factor: 4.530
Authors: Mykola V Tsapenko; Arseniy V Tsapenko; Thomas Bo Comfere; Girish K Mour; Sunil V Mankad; Ognjen Gajic Journal: Vasc Health Risk Manag Date: 2008
Authors: John D Lang; Alvin B Smith; Angela Brandon; Kelley M Bradley; Yuliang Liu; Wei Li; D Ralph Crowe; Nirag C Jhala; Richard C Cross; Luc Frenette; Kenneth Martay; Youri L Vater; Alexander A Vitin; Gregory A Dembo; Derek A Dubay; J Steven Bynon; Jeff M Szychowski; Jorge D Reyes; Jeffrey B Halldorson; Stephen C Rayhill; Andre A Dick; Ramasamy Bakthavatsalam; Jared Brandenberger; Jo Ann Broeckel-Elrod; Laura Sissons-Ross; Terry Jordan; Lucinda Y Chen; Arunotai Siriussawakul; Devin E Eckhoff; Rakesh P Patel Journal: PLoS One Date: 2014-02-12 Impact factor: 3.240
Authors: Granville G de Oliveira; Samer A H de Oliveira; Paulo Henrique H Botelho; Marcos Aurelio Barboza de Oliveira; Ka Bian; Ferid Murad Journal: Braz J Cardiovasc Surg Date: 2017 Jul-Aug